References
1. Wiener ES, Anderson JR, Ojimba JI, et al. Controversies in the
management of paratesticular rhabdomyosarcoma: is staging
retroperitoneal lymph node dissection necessary for adolescents with
resected paratesticular rhabdomyosarcoma? Semin Pediatr Surg . Aug
2001;10(3):146-52. doi:10.1053/spsu.2001.24695
2. Meza JL, Anderson J, Pappo AS, Meyer WH, Children’s Oncology G.
Analysis of prognostic factors in patients with nonmetastatic
rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and
IV: the Children’s Oncology Group. J Clin Oncol . Aug 20
2006;24(24):3844-51. doi:10.1200/JCO.2005.05.3801
3. Dang ND, Dang PT, Samuelian J, Paulino AC. Lymph node management in
patients with paratesticular rhabdomyosarcoma: a population-based
analysis. Cancer . Sep 1 2013;119(17):3228-33.
doi:10.1002/cncr.28198
4. Ecker BL, Peters MG, McMillan MT, et al. Implications of Lymph Node
Evaluation in the Management of Resectable Soft Tissue Sarcoma.Ann Surg Oncol . Feb 2017;24(2):425-433.
doi:10.1245/s10434-016-5641-1
5. Lobeck I, Dupree P, Karns R, Rodeberg D, von Allmen D, Dasgupta R.
Quality assessment of lymph node sampling in rhabdomyosarcoma: A
surveillance, epidemiology, and end results (SEER) program study.J Pediatr Surg . Apr 2017;52(4):614-617.
doi:10.1016/j.jpedsurg.2016.08.024
6. Hamilton EC, Miller CC, 3rd, Joseph M, Huh WW, Hayes-Jordan AA,
Austin MT. Retroperitoneal lymph node staging in paratesticular
rhabdomyosarcoma-are we meeting expectations? J Surg Res . Apr
2018;224:44-49. doi:10.1016/j.jss.2017.11.051
7. Brady AC, Picado O, Tashiro J, Sola JE, Perez EA. Lymph Node Sampling
and Survival in Child and Adolescent Extremity Soft-Tissue Sarcoma.J Surg Res . Sep 2019;241:205-214. doi:10.1016/j.jss.2019.03.030
8. Routh JC, Dasgupta R, Chi YY, et al. Impact of local control and
surgical lymph node evaluation in localized paratesticular
rhabdomyosarcoma: A report from the Children’s Oncology Group Soft
Tissue Sarcoma Committee. Int J Cancer . Dec 1
2020;147(11):3168-3176. doi:10.1002/ijc.33143
9. Maduekwe UN, Herb JN, Esther RJ, Kim HJ, Spanheimer PM. Pathologic
nodal staging for clinically node negative soft tissue sarcoma of the
extremities. J Surg Oncol . May 2021;123(8):1792-1800.
doi:10.1002/jso.26465
10. Liu QK, Yu XJ, Wang YG, et al. Risk factors for lymph node
metastasis of soft tissue sarcomas of the head, neck, and extremities,
and the clinical significance of negative lymph node dissection. J
Orthop Surg Res . Mar 18 2022;17(1):167. doi:10.1186/s13018-022-03050-3
11. Abdelazim YA, Zaki MF, Abdel Mohsen MM, et al. Treatment results of
Para-Testicular Rhabdomyosarcoma (PT-RMS) using radiation as an
alternative to retro-peritoneal nodal dissection: A single Institution
experience. Arch Ital Urol Androl . Nov 15 2023;95(4):11642.
doi:10.4081/aiua.2023.11642
12. Wharam MD, Meza J, Anderson J, et al. Failure pattern and factors
predictive of local failure in rhabdomyosarcoma: a report of group III
patients on the third Intergroup Rhabdomyosarcoma Study. J Clin
Oncol . May 15 2004;22(10):1902-8. doi:10.1200/JCO.2004.08.124
13. Lawrence W, Jr., Hays DM, Heyn R, et al. Lymphatic metastases with
childhood rhabdomyosarcoma. A report from the Intergroup
Rhabdomyosarcoma Study. Cancer . Aug 15 1987;60(4):910-5.
doi:10.1002/1097-0142(19870815)60:4<910::aid-cncr2820600433>3.0.co;2-8
14. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup
Rhabdomyosarcoma Study. J Clin Oncol . Mar 1995;13(3):610-30.
doi:10.1200/JCO.1995.13.3.610
15. Hibbitts E, Chi YY, Hawkins DS, et al. Refinement of risk
stratification for childhood rhabdomyosarcoma using FOXO1 fusion status
in addition to established clinical outcome predictors: A report from
the Children’s Oncology Group. Cancer Med . Oct
2019;8(14):6437-6448. doi:10.1002/cam4.2504
16. Harrison DJ, Qumseya A, Xue W, et al. Adolescents and young adults
with rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee
of the Children’s Oncology Group. Pediatr Blood Cancer . Apr
2024;71(4):e30847. doi:10.1002/pbc.30847
17. Smith LM, Anderson JR, Qualman SJ, et al. Which patients with
microscopic disease and rhabdomyosarcoma experience relapse after
therapy? A report from the soft tissue sarcoma committee of the
children’s oncology group. J Clin Oncol . Oct 15
2001;19(20):4058-64. doi:10.1200/JCO.2001.19.20.4058
18. Blatt J, Snyderman C, Wollman MR, et al. Delayed resection in the
management of non-orbital rhabdomyosarcoma of the head and neck in
childhood. Med Pediatr Oncol . Apr 1997;28(4):294-8.
doi:10.1002/(sici)1096-911x(199704)28:4<294::aid-mpo9>3.0.co;2-d
19. Lautz TB, Xue W, Luo LY, et al. Management and outcomes of chest
wall rhabdomyosarcoma: A report from the Children’s Oncology Group Soft
Tissue Sarcoma Committee. Pediatr Blood Cancer . Jul
2023;70(7):e30357. doi:10.1002/pbc.30357
20. Rogers T, Zanetti I, Coppadoro B, et al. Perianal/perineal
rhabdomyosarcoma: Results of the SIOP MMT 95, Italian RMS 96, and EpSSG
RMS 2005 studies. Pediatr Blood Cancer . Sep 2022;69(9):e29739.
doi:10.1002/pbc.29739
21. Winter S, Fasola S, Brisse H, Mosseri V, Orbach D. Relapse after
localized rhabdomyosarcoma: Evaluation of the efficacy of second-line
chemotherapy. Pediatr Blood Cancer . Nov 2015;62(11):1935-41.
doi:10.1002/pbc.25622
22. Guerin F, Rogers T, Minard-Colin V, et al. Outcome of localized
liver-bile duct rhabdomyosarcoma according to local therapy: A report
from the European Paediatric Soft-Tissue Sarcoma Study Group (EpSSG)-RMS
2005 study. Pediatr Blood Cancer . Jul 2019;66(7):e27725.
doi:10.1002/pbc.27725
23. Terwisscha van Scheltinga SEJ, Wijnen M, Martelli H, et al. Local
staging and treatment in extremity rhabdomyosarcoma. A report from the
EpSSG-RMS2005 study. Cancer Med . Oct 2020;9(20):7580-7589.
doi:10.1002/cam4.3365
24. Wolden SL, Lyden ER, Arndt CA, et al. Local Control for
Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to
Histology, Group, Site, and Size: A Report From the Children’s Oncology
Group. Int J Radiat Oncol Biol Phys . Dec 1 2015;93(5):1071-6.
doi:10.1016/j.ijrobp.2015.08.040
25. Raney B, Stoner J, Anderson J, et al. Impact of tumor viability at
second-look procedures performed before completing treatment on the
Intergroup Rhabdomyosarcoma Study Group protocol IRS-IV, 1991-1997: a
report from the children’s oncology group. J Pediatr Surg . Nov
2010;45(11):2160-8. doi:10.1016/j.jpedsurg.2010.07.021
26. Lautz TB, Chi YY, Li M, et al. Benefit of delayed primary excision
in rhabdomyosarcoma: A report from the Children’s Oncology Group.Cancer . Jan 15 2021;127(2):275-283. doi:10.1002/cncr.33275
27. Bradley JA, Kayton ML, Chi YY, et al. Treatment Approach and
Outcomes in Infants With Localized Rhabdomyosarcoma: A Report From the
Soft Tissue Sarcoma Committee of the Children’s Oncology Group.Int J Radiat Oncol Biol Phys . Jan 1 2019;103(1):19-27.
doi:10.1016/j.ijrobp.2018.08.017
28. Cecchetto G, Carli M, Sotti G, et al. Importance of local treatment
in pediatric soft tissue sarcomas with microscopic residual after
primary surgery: results of the Italian Cooperative Study RMS-88.Med Pediatr Oncol . Feb 2000;34(2):97-101.
doi:10.1002/(sici)1096-911x(200002)34:2<97::aid-mpo4>3.0.co;2-8
29. Dall’Igna P, Bisogno G, Ferrari A, et al. Primary transcrotal
excision for paratesticular rhabdomyosarcoma: is hemiscrotectomy really
mandatory? Cancer . Apr 15 2003;97(8):1981-4.
doi:10.1002/cncr.11284
30. Hays DM, Lawrence W, Jr., Wharam M, et al. Primary reexcision for
patients with ’microscopic residual’ tumor following initial excision of
sarcomas of trunk and extremity sites. J Pediatr Surg . Jan
1989;24(1):5-10. doi:10.1016/s0022-3468(89)80290-8
31. Bisogno G, Jenney M, Bergeron C, et al. Addition of dose-intensified
doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS
2005): a multicentre, open-label, randomised controlled, phase 3 trial.Lancet Oncol . Aug 2018;19(8):1061-1071.
doi:10.1016/S1470-2045(18)30337-1
32. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup
Rhabdomyosarcoma Study-I. A final report. Cancer . Jan 15
1988;61(2):209-20.
doi:10.1002/1097-0142(19880115)61:2<209::aid-cncr2820610202>3.0.co;2-l
33. Koscielniak E, Herbst M, Niethammer D, Treuner J. [Improved local
tumor control by early and risk-adjusted use of radiotherapy in primary
non-resectable rhabdomyosarcomas: results of CWS 81 and 86 studies].Klin Padiatr . Jul-Aug 1994;206(4):269-76. Verbesserung der
lokalen Tumorkontrolle durch einen fruhen und risikoadaptierten Einsatz
der Radiotherapie bei primar nicht resektablen Rhabdomyosarkomen:
Ergebnisse der CWS 81 und 86 Studien. doi:10.1055/s-2008-1046613
34. Sparber-Sauer M, Dietzschold M, Schonstein A, et al. Radiotherapy
and long-term sequelae in pediatric patients with parameningeal
rhabdomyosarcoma: Results of two Cooperative Weichteilsarkom
Studiengruppe (CWS) trials and one registry. Pediatr Blood
Cancer . Jan 2024;71(1):e30742. doi:10.1002/pbc.30742
35. Wharam M, Beltangady M, Hays D, et al. Localized orbital
rhabdomyosarcoma. An interim report of the Intergroup Rhabdomyosarcoma
Study Committee. Ophthalmology . Mar 1987;94(3):251-4.
36. Oberlin O, Rey A, Anderson J, et al. Treatment of orbital
rhabdomyosarcoma: survival and late effects of treatment–results of
an international workshop. J Clin Oncol . Jan 1
2001;19(1):197-204. doi:10.1200/JCO.2001.19.1.197
37. Minard-Colin V, Walterhouse D, Bisogno G, et al. Localized
vaginal/uterine rhabdomyosarcoma-results of a pooled analysis from four
international cooperative groups. Pediatr Blood Cancer . Sep
2018;65(9):e27096. doi:10.1002/pbc.27096
38. Lawrence W, Jr., Hays DM, Heyn R, Beltangady M, Maurer HM. Surgical
lessons from the Intergroup Rhabdomyosarcoma Study (IRS) pertaining to
extremity tumors. World J Surg . Oct 1988;12(5):676-84.
doi:10.1007/BF01655884
39. Lawrence W, Jr., Neifeld JP. Soft tissue sarcomas. Curr Probl
Surg . Nov 1989;26(11):753-827. doi:10.1016/0011-3840(89)90036-1
40. Blakely ML, Andrassy RJ, Raney RB, et al. Prognostic factors and
surgical treatment guidelines for children with rhabdomyosarcoma of the
perineum or anus: a report of Intergroup Rhabdomyosarcoma Studies I
through IV, 1972 through 1997. J Pediatr Surg . Mar
2003;38(3):347-53. doi:10.1053/jpsu.2003.50106
41. Andrassy RJ, Wiener ES, Raney RB, et al. Progress in the surgical
management of vaginal rhabdomyosarcoma: a 25-year review from the
Intergroup Rhabdomyosarcoma Study Group. J Pediatr Surg . May
1999;34(5):731-4; discussion 734-5. doi:10.1016/s0022-3468(99)90365-2
42. Flamant F, Rodary C, Voute PA, Otten J. Primary chemotherapy in the
treatment of rhabdomyosarcoma in children: trial of the International
Society of Pediatric Oncology (SIOP) preliminary results.Radiother Oncol . Apr 1985;3(3):227-36.
doi:10.1016/s0167-8140(85)80031-1
43. Heyn R, Newton WA, Raney RB, et al. Preservation of the bladder in
patients with rhabdomyosarcoma. J Clin Oncol . Jan
1997;15(1):69-75. doi:10.1200/JCO.1997.15.1.69
44. Lautz TB, Chi YY, Tian J, et al. Relationship between tumor response
at therapy completion and prognosis in patients with Group III
rhabdomyosarcoma: A report from the Children’s Oncology Group. Int
J Cancer . Sep 1 2020;147(5):1419-1426. doi:10.1002/ijc.32896
45. Rodeberg DA, Stoner JA, Hayes-Jordan A, et al. Prognostic
significance of tumor response at the end of therapy in group III
rhabdomyosarcoma: a report from the children’s oncology group. J
Clin Oncol . Aug 1 2009;27(22):3705-11. doi:10.1200/JCO.2008.19.5933
46. Hays DM, Raney RB, Crist WM, et al. Secondary surgical procedures to
evaluate primary tumor status in patients with chemotherapy-responsive
stage III and IV sarcomas: a report from the Intergroup Rhabdomyosarcoma
Study. J Pediatr Surg . Oct 1990;25(10):1100-5.
doi:10.1016/0022-3468(90)90228-2
47. Regine WF, Fontanesi J, Kumar P, et al. Local tumor control in
rhabdomyosarcoma following low-dose irradiation: comparison of group II
and select group III patients. Int J Radiat Oncol Biol Phys . Feb
1 1995;31(3):485-91. doi:10.1016/0360-3016(94)00352-L
48. Rodeberg DA, Wharam MD, Lyden ER, et al. Delayed primary excision
with subsequent modification of radiotherapy dose for intermediate-risk
rhabdomyosarcoma: a report from the Children’s Oncology Group Soft
Tissue Sarcoma Committee. Int J Cancer . Jul 1 2015;137(1):204-11.
doi:10.1002/ijc.29351
49. Mohan AC, Venkatramani R, Okcu MF, et al. Local therapy to distant
metastatic sites in stage IV rhabdomyosarcoma. Pediatr Blood
Cancer . Feb 2018;65(2)doi:10.1002/pbc.26859
50. Ben Arush M, Minard-Colin V, Mosseri V, et al. Does aggressive local
treatment have an impact on survival in children with metastatic
rhabdomyosarcoma? Eur J Cancer . Jan 2015;51(2):193-201.
doi:10.1016/j.ejca.2014.11.009
51. Pappo AS, Anderson JR, Crist WM, et al. Survival after relapse in
children and adolescents with rhabdomyosarcoma: A report from the
Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol . Nov
1999;17(11):3487-93. doi:10.1200/JCO.1999.17.11.3487
52. Chisholm JC, Marandet J, Rey A, et al. Prognostic factors after
relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define
patients who can be salvaged with further therapy. J Clin Oncol .
Apr 1 2011;29(10):1319-25. doi:10.1200/JCO.2010.32.1984
53. Sparber-Sauer M, Stegmaier S, Vokuhl C, et al. Rhabdomyosarcoma
diagnosed in the first year of life: Localized, metastatic, and relapsed
disease. Outcome data from five trials and one registry of the
Cooperative Weichteilsarkom Studiengruppe (CWS). Pediatr Blood
Cancer . Jun 2019;66(6):e27652. doi:10.1002/pbc.27652
54. Heinz AT, Ebinger M, Schonstein A, et al. Second-line treatment of
pediatric patients with relapsed rhabdomyosarcoma adapted to initial
risk stratification: Data of the European Soft Tissue Sarcoma Registry
(SoTiSaR). Pediatr Blood Cancer . Jul 2023;70(7):e30363.
doi:10.1002/pbc.30363
55. Bergamaschi L, Chiaravalli S, Livellara V, et al. Relapse after
nonmetastatic rhabdomyosarcoma: Salvage rates and prognostic variables.Pediatr Blood Cancer . Jan 2023;70(1):e30050.
doi:10.1002/pbc.30050
56. Hayes-Jordan A, Doherty DK, West SD, et al. Outcome after surgical
resection of recurrent rhabdomyosarcoma. J Pediatr Surg . Apr
2006;41(4):633-8; discussion 633-8. doi:10.1016/j.jpedsurg.2005.12.002
57. De Corti F, Bisogno G, Dall’Igna P, et al. Does surgery have a role
in the treatment of local relapses of non-metastatic rhabdomyosarcoma?Pediatr Blood Cancer . Dec 15 2011;57(7):1261-5.
doi:10.1002/pbc.23225
58. Dantonello TM, Int-Veen C, Schuck A, et al. Survival following
disease recurrence of primary localized alveolar rhabdomyosarcoma.Pediatr Blood Cancer . Aug 2013;60(8):1267-73.
doi:10.1002/pbc.24488
59. Fetzko S, Fonseca A, Frances Wedekind M, et al. Is Detection of
Relapse by Surveillance Imaging Associated With Longer Survival in
Patients With Rhabdomyosarcoma? J Pediatr Hematol Oncol . Aug 1
2022;44(6):305-312. doi:10.1097/MPH.0000000000002429
60. Raney B, Huh W, Hawkins D, et al. Outcome of patients with localized
orbital sarcoma who relapsed following treatment on Intergroup
Rhabdomyosarcoma Study Group (IRSG) Protocols-III and -IV, 1984-1997: a
report from the Children’s Oncology Group. Pediatr Blood Cancer .
Mar 2013;60(3):371-6. doi:10.1002/pbc.24289
61. Mazzoleni S, Bisogno G, Garaventa A, et al. Outcomes and prognostic
factors after recurrence in children and adolescents with nonmetastatic
rhabdomyosarcoma. Cancer . Jul 1 2005;104(1):183-90.
doi:10.1002/cncr.21138
62. Dantonello TM, Int-Veen C, Winkler P, et al. Initial patient
characteristics can predict pattern and risk of relapse in localized
rhabdomyosarcoma. J Clin Oncol . Jan 20 2008;26(3):406-13.
doi:10.1200/JCO.2007.12.2382
63. Mattke AC, Bailey EJ, Schuck A, et al. Does the time-point of
relapse influence outcome in pediatric rhabdomyosarcomas? Pediatr
Blood Cancer . Jul 2009;52(7):772-6. doi:10.1002/pbc.21906
64. Blakely ML, Lobe TE, Anderson JR, et al. Does debulking improve
survival rate in advanced-stage retroperitoneal embryonal
rhabdomyosarcoma? J Pediatr Surg . May 1999;34(5):736-41;
discussion 741-2. doi:10.1016/s0022-3468(99)90366-4
65. Cecchetto G, Bisogno G, De Corti F, et al. Biopsy or debulking
surgery as initial surgery for locally advanced rhabdomyosarcomas in
children?: the experience of the Italian Cooperative Group studies.Cancer . Dec 1 2007;110(11):2561-7. doi:10.1002/cncr.23079
66. Spunt SL, Lobe TE, Pappo AS, et al. Aggressive surgery is
unwarranted for biliary tract rhabdomyosarcoma. J Pediatr Surg .
Feb 2000;35(2):309-16. doi:10.1016/s0022-3468(00)90030-7
Table S1: The priority questions guiding the evidence
review and synthesis for the guidelines.